Sanofi has discontinued a Phase 2 clinical trial of oditrasertib, a Denali-partnered drug, for multiple sclerosis after it failed to meet primary or key secondary endpoints.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.